• Young Ho Yun, Tito R Mendoza, Dae Seog Heo, Taiwoo Yoo, Bong Yul Heo, Hyeoun-Ae Park, Ho Cheol Shin, Xin Shelley Wang, and Charles S Cleeland.
• Research Institute and Hospital, National Cancer Center, Goyang, Korea.
• Oncology. 2004 Jan 1;66(6):439-44.

ObjectiveThe aim of this study was to validate the Korean version of the Brief Pain Inventory (BPI-K), a pain assessment tool that has been validated in several languages.MethodsThe sample consisted of 132 patients in Seoul who had recurrent or metastatic cancer and who expressed pain. The Korean version of the Beck Depression Inventory (BDI-K), the Eastern Cooperative Oncology Group (ECOG) performance status score, the Pain Management Index (PMI), and the PMI-Revised (PMI-R) were used to further validate the BPI-K.ResultsCronbach alphas, computed for the pain interference and pain severity item, were 0.93 and 0.85, respectively. Confirmatory factor analysis of the BPI-K items showed a two-common-factor solution for the BPI-K, consistently demonstrated in other language versions of the BPI. The mean pain interference score was more correlated with the BDI-K scale (r = 0.44) and ECOG (r = 0.39) than the mean pain severity score. Seventy-four percent of the patients in the Seoul sample had inadequate analgesia using the PMI.ConclusionThe BPI-K is a valid and useful instrument for assessing cancer pain and pain impact in Korea.Copyright 2004 S. Karger AG, Basel

22 keywords...

hide…